Mifamurtide
- Generic Name
- Mifamurtide
- Brand Names
- Mepact
- Drug Type
- Small Molecule
- Chemical Formula
- C59H110N6NaO20P
- CAS Number
- 83461-56-7
- Unique Ingredient Identifier
- 1LM890Q4FY
- Background
Mifamurtide is an immunomodulator with antitumor activity via activation of macrophages and monocytes. Also called L-MTP-PE, mifamurtide may be a liposomal form of of the active ingredient MTP-PE, which is a synthetic, less pyrogenic, and longer-acting derivative of muramyl dipeptide (MDP). MDP is a motif present in all gram-positive and gram-negative bacter...
- Indication
Indicated in children, adolescents and young adults for the treatment of high-grade, resectable, non-metastatic osteosarcoma after macroscopically complete surgical resection, typically in combination with post-operative multi-agent chemotherapy .
- Associated Conditions
- High-grade, nonmetastatic Osteosarcoma, Resectable, nonmetastatic Osteosarcoma
- Associated Therapies
- -
Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients
- Conditions
- Interventions
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 60
- Registration Number
- NCT03643133
- Locations
- 🇫🇷
CHU de Nice - Service d'oncologie hématologie pédiatrique, Nice, France
🇫🇷CHU Toulouse - Hôpital des Enfants - Service d'Hémato-Immuno-Oncologie, Toulouse, France
🇫🇷CHU de Caen - Service d'oncologie hématologie pédiatrique, Caen, France
A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 8
- Registration Number
- NCT02441309
- Locations
- 🇬🇧
Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
🇬🇧University College London Hospitals NHS Foundation Trust, London, United Kingdom
🇳🇱Department of Clinical Oncology, Leiden University Medical Center, Leiden, Postzone K1-P, Netherlands
Surveillance Study of Patients With Newly Diagnosed Osteosarcoma
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT01194284
- Locations
- 🇦🇹
AKH Wien Universitätsklinik für Innere Medizin I Klinische Abteilung für Onkologie, Wien, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.